Cardiovascular imaging AI firm Elucid has named new executives ahead of the launch of PlaqueIQ, its image analysis software. PlaqueIQ was cleared in October 2024 by the U.S. Food and Drug Administration (FDA).
The company has appointed Amir Ahmadi, MD, as its chief scientific advisor. (He has a financial relationship with Elucid in his role as chief scientific advisor, the company noted.) Ahmadi is a cardiologist at Icahn School of Medicine at Mount Sinai in New York. His ongoing clinical practice and research focus on using CT coronary angiography to detect and treat subclinical atherosclerosis, understand myocardial infarction mechanisms, and investigate the relationship between high-risk plaque features and ischemia, according to the firm.
It has also tapped Carol Holt as its vice president of clinical development; Kevin Mathews as senior vice president of marketing; and Amy Pyke as senior vice president of market access, Elucid said.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
